NewLink is licensing its IDO pathway inhibitor NLG919 to Genentech as part of a cancer therapy drugdiscovery collaborative partnership deal Genentech is paying NewLink $150 million up front in a deal that could be worth as much as $115 billion |
Thứ Ba, 21 tháng 10, 2014
Genentech strikes rare $1.15B cancer pact with NewLink Genetics
